Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 13Phase 3 7Phase EARLY_PHASE1 2Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Lymphoid 5Gynecologic 4Dermatologic 3Sarcoma 2Head & Neck 2Genitourinary 2Gastrointestinal 2CNS 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Disulfides × Gastrointestinal × Clear all
NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

City of Hope Medical Center

Phase 1/2 Active not recruiting
20 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡